Voyager Therapeutics Inc
VYGR
$7.57
Closing
▼-1.05%
1D
▼-10.31%
YTD
Market cap
$411.06M
52 week high
$14.33
52 week low
$6.06
Volume
147,234
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$411.06M
Analysts' Rating
BUY
Price Target (Mean)
13.66667
Total Analysts
7
P/E
2.56
Operating Margin
-639.51%
Beta
0.99
Revenue Growth (Annual)
9.33%
52 week high
$14.33
52 week low
$6.06
Div. Yield
%
EPS Annual Growth
15.78
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Voyager Therapeutics, Inc. is a biotechnology company. The Company focuses on leveraging its expertise in capsid discovery and neuropharmacology to address the delivery hurdles that have constrained the gene therapy and neurology disciplines. Its gene therapy platforms enable it to engineer, optimize, manufacture and deliver its adeno-associated virus (AAV)-based gene therapies. It is identifying AAV capsids, the outer viral protein shells that enclose genetic material that makes up the vector payload. It has developed an AAV capsid discovery platform called Tropism Redirection of AAV by Cell Type-Specific Expression of RNA (TRACERTM) that employs directed evolution to facilitate the selection of AAV capsids with enhanced tissue delivery characteristics, such as more effective delivery across the blood brain barrier (BBB). Its pipeline programs include superoxide dismutase 1 (SOD1), gene therapy for amyotrophic lateral sclerosis (ALS), and an anti-tau antibody for Alzheimer’s disease.
